BACKGROUND: The K65R HIV-1 reverse transcriptase (RT) mutation is a multidrug resistance mutation which may be correlated with specific antiretroviral combinations and with the presence or absence of other RT resistance mutations. OBJECTIVES: The aims of this study were: (i) to determine the prevalence of the K65R mutation in a cohort of antiretroviral-treated patients; (ii) to study genotypic patterns and treatment characteristics in patients in whom the K65R mutation was present. STUDY DESIGN: We included in the study all antiretroviral-experienced patients followed up at the Bordeaux University Hospital in 2003 and 2004 for whom an HIV-1 genotypic resistance analysis was available. Information on RT resistance mutations was reported from a hospital database including therapeutic and biological parameters. The prevalence of K65R was investigated for all patients. Genotypic patterns and treatment characteristics were examined at the time of detection of the K65R mutation. RESULTS: The prevalence of K65R was 1.9% (26 of 1404 patients). K65R was associated with nucleoside RT inhibitor-based regimens in 22 patients, and with tenofovir disoproxil fumarate, lamivudine, didanosine and abacavir in 23, 17, 17 and eight patients, respectively. The M184V and Q151M mutations were the most commonly co-selected substitutions. Thymidine analogue mutations (TAMs) were rarely co-selected with K65R and inversely associated with K65R. CONCLUSION: The K65R mutation may emerge preferentially in the absence of zidovudine and TAMs, suggesting the possibility of an antagonistic interaction between K65 and TAMs.
BACKGROUND: The K65RHIV-1 reverse transcriptase (RT) mutation is a multidrug resistance mutation which may be correlated with specific antiretroviral combinations and with the presence or absence of other RT resistance mutations. OBJECTIVES: The aims of this study were: (i) to determine the prevalence of the K65R mutation in a cohort of antiretroviral-treated patients; (ii) to study genotypic patterns and treatment characteristics in patients in whom the K65R mutation was present. STUDY DESIGN: We included in the study all antiretroviral-experienced patients followed up at the Bordeaux University Hospital in 2003 and 2004 for whom an HIV-1 genotypic resistance analysis was available. Information on RT resistance mutations was reported from a hospital database including therapeutic and biological parameters. The prevalence of K65R was investigated for all patients. Genotypic patterns and treatment characteristics were examined at the time of detection of the K65R mutation. RESULTS: The prevalence of K65R was 1.9% (26 of 1404 patients). K65R was associated with nucleoside RT inhibitor-based regimens in 22 patients, and with tenofovir disoproxil fumarate, lamivudine, didanosine and abacavir in 23, 17, 17 and eight patients, respectively. The M184V and Q151M mutations were the most commonly co-selected substitutions. Thymidine analogue mutations (TAMs) were rarely co-selected with K65R and inversely associated with K65R. CONCLUSION: The K65R mutation may emerge preferentially in the absence of zidovudine and TAMs, suggesting the possibility of an antagonistic interaction between K65 and TAMs.
Authors: Philip M Grant; Jonathan Taylor; Andrew B Nevins; Vincent Calvez; Anne-Geneviève Marcelin; Marc Wirden; Andrew R Zolopa Journal: Antimicrob Agents Chemother Date: 2010-02-01 Impact factor: 5.191
Authors: D Rajotte; S Tremblay; A Pelletier; P Salois; L Bourgon; R Coulombe; S Mason; L Lamorte; C F Sturino; R Bethell Journal: Antimicrob Agents Chemother Date: 2013-04-01 Impact factor: 5.191
Authors: S Di Giambenedetto; C Torti; M Prosperi; N Manca; G Lapadula; G Paraninfo; N Ladisa; M Zazzi; M Trezzi; P Cicconi; P Corsi; P Nasta; R Cauda; A De Luca Journal: Infection Date: 2009-08-07 Impact factor: 3.553
Authors: Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips Journal: PLoS One Date: 2012-08-08 Impact factor: 3.240
Authors: Allison Navis; Ifunanya Dallah; Charles Mabeta; Kalo Musukuma; Omar K Siddiqi; Christopher M Bositis; Igor J Koralnik; Harris A Gelbard; William H Theodore; Jason F Okulicz; Brent A Johnson; Izukanji Sikazwe; David R Bearden; Gretchen L Birbeck Journal: Epilepsia Date: 2020-10-21 Impact factor: 5.864
Authors: Claudia A Hawkins; Beth Chaplin; John Idoko; Ernest Ekong; Isaac Adewole; Wadzani Gashau; Robert L Murphy; Phyllis Kanki Journal: J Acquir Immune Defic Syndr Date: 2009-10-01 Impact factor: 3.731